Their work indicated that a telomerase-targeting strategy could induce senescence in CML-like cells and alleviate the tumor promoting/progressing effect of BCR-ABL [39]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.